Aspira Women’s Health Inc. (NASDAQ:AWH) Sees Large Increase in Short Interest

Posted by Donna Armstrong on Mar 18th, 2025

Aspira Women’s Health Inc. (NASDAQ:AWH – Get Free Report) saw a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 1,510,000 shares, a growth of 28.0% from the February 13th total of 1,180,000 shares. Currently, 12.0% of the company’s shares are sold short. Based on an average daily volume of 301,100 shares, the short-interest ratio is presently 5.0 days.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Aspira Women’s Health in a research note on Sunday, January 12th. They set a “hold” rating on the stock.

Get Our Latest Analysis on AWH

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. boosted its stake in Aspira Women’s Health Inc. (NASDAQ:AWH – Free Report) by 33.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 316,294 shares of the company’s stock after purchasing an additional 79,898 shares during the period. B. Riley Wealth Advisors Inc. owned approximately 1.90% of Aspira Women’s Health worth $256,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 12.19% of the company’s stock.

Aspira Women’s Health Trading Down 7.2 %

Shares of AWH opened at $0.13 on Tuesday. The firm has a market capitalization of $2.30 million, a P/E ratio of -0.11 and a beta of 1.57. The stock’s fifty day simple moving average is $0.34 and its 200 day simple moving average is $0.65. Aspira Women’s Health has a twelve month low of $0.12 and a twelve month high of $3.81.

About Aspira Women’s Health

(Get Free Report)

Aspira Women’s Health, Inc engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.